December 27, 2007 - GE Healthcare announced today that it has entered into an agreement with DRAXIMAGE, a division of DRAXIS Health Inc. of Montreal, Canada, to become the exclusive distributor of DRAXIMAGE Sestamibi upon its approval by the FDA and the expiration of the primary innovator patent.
An abbreviated New Drug Application (ANDA) for DRAXIMAGE Sestamibi was submitted by DRAXIMAGE to the FDA in February 2007, and is currently under review.
